2024-518908-46-00RecruitingPhase 3
Use of [18F]FET PET-MRI to improve detection of pituitary adenomas in Cushing’s disease
Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)1 site in 1 country30 target enrollmentStarted: May 15, 2025Last updated:
Drugs
Trial Snapshot
- Phase
- Phase 3
- Status
- Recruiting
- Enrollment
- 30
- Locations
- 1
- Primary Endpoint
- The primary endpoint of this prospective evaluation is the difference in the proportion of patients with ACTH-dependent hypercortisolism in whom CD is correctly distinguished from ectopic CS using [18F]FET PET-MRI versus IPSS. [18F]FET PET-MRI will be compared for non-inferiority to the current standard IPSS.
Study Overview
Brief Summary
The main objective is to compare the proportion of patients with ACTH-dependent hypercortisolism in whom Cushing's disease (CD) is correctly differentiated from ectopic Cushing's syndrome (CS) using [18F]FET PET-MRI compared to IPSS.
Eligibility Criteria
- Ages
- 18 years to 65+ years (18-64 Years, 65+ Years)
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •In order to be eligible to participate in this study, a subject must meet all of the following criteria:
- •Age ≥18 years
- •Biochemically confirmed ACTH-dependent hypercortisolism, defined as: Non-suppressed ACTH levels plus minimal 2 of the following: Overnight 1mg dexamethasone suppression test > 50 nmol/L; and/or Elevated late night salivary cortisol (min. 2/3 measurements); and/or Elevated 24-hours urinary free cortisol (min. 2 measurements)
- •Pituitary microadenoma (< 10mm) OR negative / inconclusive findings on standard MRI of the pituitary sella-region.
- •Indication for further evaluation with IPSS.
Exclusion Criteria
- •A potential subject who meets any of the following criteria will be excluded from participation in this study:
- •Non-ACTH dependent hypercortisolism;
- •Pituitary macroadenoma (≥ 10mm);
- •Suspicion of Pseudo-Cushing’s disease (e.g. due to alcohol use disorder, PCO’s, obesity, depression) according to standard work up / guidelines;
- •Use of glucocorticosteroids;
- •Impaired renal function, defined as eGFR (MDRD) <30ml/min/1,73 m
- •An exception can be made in consultation with the treating physician;
- •Impaired Liver function;
- •Pregnancy/breastfeeding. For the latter, temporary discontinuation may be considered;
- •Known allergic reaction to therapeutic radiopharmaceuticals;
- •Inability to lie still in supine position for the duration of the PET-MRI scan;
- •Other conditions that make it impossible to perform a PET-MRI scan, such as neurological disease, severe immobility, or unsuppressable claustrophobia.
Outcomes
Primary Outcomes
The primary endpoint of this prospective evaluation is the difference in the proportion of patients with ACTH-dependent hypercortisolism in whom CD is correctly distinguished from ectopic CS using [18F]FET PET-MRI versus IPSS. [18F]FET PET-MRI will be compared for non-inferiority to the current standard IPSS.
The primary endpoint of this prospective evaluation is the difference in the proportion of patients with ACTH-dependent hypercortisolism in whom CD is correctly distinguished from ectopic CS using [18F]FET PET-MRI versus IPSS. [18F]FET PET-MRI will be compared for non-inferiority to the current standard IPSS.
Secondary Outcomes
- Secondary endpoints include the sensitivity, specificity, positive and negative predictive value of the two techniques for the exact localization of ACTH-secreting PitNETs, based on post-operative neurosurgery and pathology reports as well as biochemical remission as reference standards. The area under the curve (AUC) for both techniques will be calculated from the receiver operating curve (ROC).
Investigators
drs. R. van der Groef
Scientific
Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
Study Sites (1)
Loading locations...
Similar Trials
Completed
Not Applicable
The Utility of 18F-fluorocholine PET/CT in the Imaging of Parathyroid AdenomasParathyroid AdenomaHyperparathyroidismNCT04570033Military Institute od Medicine National Research Institute65
Unknown
Not Applicable
Cortisol Response to Adrenocorticotrophin (ACTH) in Acute StressAortic Aneurysm, AbdominalNCT00493389University of Ottawa80
Recruiting
Phase 2
99mTc Sestamibi SPECT/CT vs 18F Fluorocholine PET/CTParathyroid AdenomaNCT05891769Andrei Iagaru100
Unknown
Not Applicable
18F-fluorocholine PET/CT Imaging in HyperparathyroidismHyperparathyroidismNCT03203668University Medical Centre Ljubljana1,000
Completed
Not Applicable
Combined Use of 18F-FDG PET and Corticosteroid for Diagnosis of Deep-seated Primary Central Nervous System Lymphoma without Histopathological ConfirmatioPrimary Central Nervous System LymphomaJPRN-UMIN000017401Department of Neurosurgery, Graduate School of Medicine, Hokkaido University10